# Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage

Alen Zabotti, Filippo Fagni, Laure Gossec, Ivan Giovannini, Michael

Sticherling, Annarita Tullio, Xenofon Baraliakos, Gabriele de Marco,
Salvatore de Vita, Enzo Errichetti, et al.

► To cite this version:

Alen Zabotti, Filippo Fagni, Laure Gossec, Ivan Giovannini, Michael Sticherling, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open, 2024, 10 (2), pp.e004314. 10.1136/rmdopen-2024-004314. hal-05000452

HAL Id: hal-05000452

https://hal.science/hal-05000452v1

Submitted on 21 Mar 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage

## Authors

Alen Zabotti¹, Filippo Fagni ²,³, Laure Gossec ⁸,⁹ Ivan Giovannini¹, Michael Sticherling³, ⁴, Annarita Tullio¹, Xenofon Baraliakos⁵, Gabriele De Marco⁶,⁷, Salvatore De Vita¹, Enzo Errichetti ¹, , Ettore Silvagni¹⁰, Josef S. Smolen¹¹, Ilaria Tinazzi¹², Abdulla Watad¹³, Georg Schett²,³, Dennis McGonagle⁶,⁷ and David Simon²,³.

## Affiliations

¹ Department of Medical and Biological Sciences, Rheumatology Institute, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy

²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany

³Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, German

⁴Department of Dermatology, Friedrich Alexander University Erlangen–Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany

⁵ Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Germany

⁶Leeds Musculoskeletal Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK.

⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

⁸INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France.

⁹APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.

¹⁰Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Cona, Ferrara, Italy

¹¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Wien, Austria.

¹²Unit of Rheumatology, Don Calabria Sacred Heart Hospital, Negrar, Italy

¹³Internal Medicine, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel.

## Correspondence

Alen Zabotti, Rheumatology Institute, Department of Medicine, University of Udine, c/o Azienda Sanitaria Universitaria Friuli Centrale, Piazzale Santa Maria della Misericordia 15, 33100 Udine, Italy.

e-mail. zabottialen@gmail.com
**Abstract**

**Objective** Subjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis.

**Methods** Patients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts. The key outcome was new-onset PsA. Musculoskeletal symptoms including inflammatory and non-inflammatory symptoms before PsA diagnosis were collected. Occurrence of PsA was analysed with survival analysis and cumulative incidence functions (CIFs).

**Results** 384 patients with PsO were included with a mean follow-up of 33.0 (±20.9) months. 311 of 384 (80.9%) had subclinical PsA with a PsA incidence rate of 7.7 per 100 patient-years. Subclinical PsA displayed a higher risk of PsA development compared with PsO (HR=11.7 (95% CI 1.57 to 86.7), p=0.016). The probability of new-onset PsA estimated by the CIF was 9.4% (95% CI 4.7% to 10.6%) at month 12 and 22.7% (95% CI 17.2% to 28.6%) at month 36. 58.9% of cases reported inflammatory symptoms in the months immediately prior to PsA diagnosis but prior non-inflammatory symptoms were evident in 83.9% prior to PsA diagnosis. Peripheral joint swelling was the predominant PsA presentation pattern (82.1%).

**Conclusions** The probability of PsA development among subclinical PsA was relatively high, emphasising the importance of emergent musculoskeletal symptoms when aiming for PsA prevention. Joint swelling was the dominant feature in new-onset PsA, likely reflecting clinical confidence in recognising joint swelling.
# HIGHLIGHTS

## WHAT IS ALREADY KNOWN ON THIS TOPIC

* Limited and controversial information has been made available concerning the progression from psoriasis (PsO) to psoriatic arthritis (PsA). A more comprehensive grasp of the phases occurring prior to the onset of PsA could streamline the early detection of PsA and the development of novel preventive treatment approaches. Recently, a European Alliance of Associations for Rheumatology task force has proposed a nomenclature that represents a temporal continuum of psoriatic disease. This continuum comprises: (a) a stage of being at higher risk in patients with PsO (eg, nail involvement); (b) the 'subclinical stage', encompassing clinical attributes like arthralgia and/or imaging findings; and (c) the 'clinical' stage, which is defined by the presence of clinical synovitis in individuals with PsO.

## WHAT THIS STUDY ADDS

* In patients with PsO identified as having subclinical PsA due to the presence of arthralgia, we determined a 9.4% probability of developing PsA within the initial 12 months of follow-up, increasing to 22.7% after 36 months. Peripheral arthritis was the predominant presentation pattern (82.1%), with oligoarthritis being particularly common. Remarkably, musculoskeletal symptoms often persisted for an extended period and, in many cases, exhibited a 'non-inflammatory' nature in the months leading up to the diagnosis of PsA.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

* This study emphasises the necessity to enhance the identification of symptoms in the subclinical PsA. Such improvement can significantly bolster our capability to spot PsA in its early stages, allowing for a swifter diagnosis and the possibility of preventative or interceptive actions.
Introduction

Psoriatic arthritis (PsA) affects up to one-third of people with psoriasis (PsO) and in about 70% of
these cases, skin and/or nail involvement precedes the onset of PsA.<sup>1–3</sup> The lack of a biomarker
similar to anticitrullinated protein antibodies in preclinical rheumatoid arthritis (RA) complicates the
study of PsO to PsA transition.<sup>4–5</sup> Thus far, limited and controversial data have been published
regarding the transition from PsO to PsA.<sup>6,7</sup> A better understanding of the phases before PsA onset
could facilitate early PsA detection and designing new preventative treatment strategies.<sup>8</sup>

It has been suggested that the development of PsA within clinically meaningful time frames can be
predicted using readily available clinical variables, including prodromal symptoms of PsA and
phenotypical features of PsO.<sup>9 10</sup> However, these prediction tools are preliminary and need further
validation. Recently, a European Alliance of Associations for Rheumatology (EULAR) task force
developed points to consider for the definition of clinical and imaging features suspicious for
progression to PsA.<sup>11</sup> A nomenclature reflecting a temporal, although non-linear continuum, of
psoriatic disease was proposed: (a) a stage of being ‘at higher risk’ in patients with PsO (eg,
severe skin involvement, nail involvement); (b) the ‘subclinical stage’, including clinical features,
namely arthralgia and/or imaging features typically linked to more imminent progression to PsA;
and (c) the ‘clinical’ stage defined by the presence of clinical synovitis in an individual with PsO.<sup>11</sup>

A recent systematic literature review⁶ informing this EULAR project highlighted the fragmentary
knowledge on the transition from PsO to PsA. Thus, it appeared there is a major unmet need for
the characterisation of the symptoms before the clinical onset of PsA, as well as the clinical
features at the moment of diagnosis of PsA.<sup>12–14</sup> These could help to better define outcomes for
PsA prevention studies in the context of prevention/interception of PsA and early
diagnosis.<sup>9</sup> Therefore, this study investigated the subclinical stage of PsA in terms of risk of
progression and clinical symptoms, and to describe the clinical features of new-onset PsA in PsO
cases.
## Patients and methods

Data from two European prospective cohorts of patients with PsO were analysed. The Italian cohort, RAPSODI (UltRasonographic risk fActors to develoP pSOriatic arthritis in psoriatic patients with anD without clinical arthralgia),¹⁵ and the German PACE cohort (Psoriasis and Psoriatic Arthritis Cohort Erlangen) are both ongoing longitudinal studies.¹⁶ ¹⁷ Subjects had definite PsO of skin or nails diagnosed by a dermatologist. The two cohorts were enriched for risk of PsA, with a high proportion of patients with significant short-term risks of PsA development due to the presence of arthralgia.¹⁶

The patients were defined as subclinical PsA solely based on the presence of arthralgia. Imaging was not used to identify subclinical forms, and it was beyond the scope of the study to assess whether the presence of musculoskeletal (MSK) inflammation detected by imaging was a predictor of PsA development.

The patients analysed did not have PsA at entry in the cohort and no patient had visible joint swelling at the time of inclusion in the cohorts.¹⁵ Indeed, in both cohorts, all subjects with PsO were evaluated by a rheumatologist and patients with joint swelling, dactylitis, clinical signs of enthesitis or inflammatory back pain and, in general, those fulfilling the Classification of Psoriatic Arthritis (CASPAR) criteria,¹⁸ were excluded before enrolment.

To exclude past MSK involvement, medical history and patient records were also reviewed. Identification of a history of synovitis, enthesitis, dactylitis and/or inflammatory back pain in the past or evidence of meeting the CASPAR criteria at any time also led to exclusion. In both cohorts during the study follow-up, patients with PsO were reassessed every 6 months and patients were instructed to contact the rheumatologist prior to their scheduled assessment if they developed inflammatory symptoms (eg, worsening of joint pain or onset of joint swelling).

### Patients with PsO from the RAPSODI cohort

Between January 2017 and 31 December 2022, 215 patients with PsO attending the Dermatology Department of three Italian hospitals (Udine, Negrar-Verona and Ferrara) were enrolled into the RAPSODI cohort.¹⁵ 142 of 215 patients with PsO (66.0%) described arthralgia not explained by other diagnoses at baseline and are analysed, for the purpose of this study, as subclinical PsA. The remaining 73 of 215 (34%) patients with PsO did not report arthralgia and/or other symptoms potentially associated with PsA. The mean follow-up of the 215 patients with PsO was 35.9 (±16.9) months and the median was 41 (IQR 21–59) months.

### Patients with PsO from the PACE cohort

Between January 2011 and July 2018, 169 patients with PsO attending the Dermatology Department of the University of Erlangen-Nuremberg (Germany) were enrolled into the PACE cohort, as detailed elsewhere.¹⁶ Briefly, patients had definite PsO and had to answer positively to at least one of the questions of the GERman Psoriatic Arthritis Diagnostic Questionnaire, that is, all subjects presented with arthralgia and/or low back pain not explained by other diagnoses¹⁹ ²⁰; therefore, all are considered here as subclinical PsA. The mean follow-up was 25.3 (±15.2) months, while the median was 20 (IQR 12–33) months.

### Case definition and characteristics of new-onset clinical PsA

During the follow-up, incident new-onset clinical PsA was defined by the diagnosis of an experienced rheumatologist and with the fulfilment of CASPAR criteria (score ≥3 points).¹⁸

The predominant manifestations of new-onset clinical PsA were described and to this end, at the visit where PsA was established, we characterised the type of PsA involvement. Peripheral manifestations were defined clinically: peripheral arthritis was defined by joint swelling, and dactylitis (a manifestation of digit swelling clinically including tenosynovitis and synovitis) was determined by clinical examination. With respect to peripheral arthritis, polyarticular disease was defined as five or more active (ie, swollen) joints, while oligoarthritis was defined as four or less active (swollen) joints according to Gossec et al.¹²
Enthesitis was defined by enthesal pain confirmed by ultrasound in the lateral humeral epicondyle, proximal and distal patellar insertion, plantar fascia (only in the RAPSODI cohort) and Achilles tendon insertion. Active enthesitis was ultrasonographically defined according to the OMERACT definition.²¹ Axial involvement was determined by a combination of inflammatory back pain and imaging evidence of sacroiliitis or spondylitis on X-rays or MRI.²² ²³ At PsA diagnosis, the clinical features were collected, including gender, age, body mass index, 66 swollen and 68 tender joint count, Leeds Enthesitis Index (LEI),²⁴ ²⁵ and presence of dactylitis in hands and feet.

## Definition of MSK symptoms before PsA onset

The precise characterisation of the MSK symptoms before the onset of clinical PsA was retrospectively collected from the medical clinical charts of patients who developed PsA during the follow-up.

The MSK patterns before clinical PsA onset were defined as:

1. Inflammatory—when at least two of the following features were present: (a) duration of morning stiffness >30 min; (b) most severe symptoms present in the morning; (c) improvement of symptoms during the day.

2. Non-inflammatory—defined as arthralgia without inflammatory features.

3. Mixed—defined by a combination of non-inflammatory symptoms initially and inflammatory symptom development thereafter.

## Statistical analysis

Continuous variables were expressed as mean±SD or median and IQR according to data distribution after performing the Kolmogorov-Smirnov test for normality. Categorical variables were expressed as absolute and relative frequencies and percentages.

Occurrence of arthritis over time was analysed using survival analysis, censoring patients at last follow-up. We calculated the cumulative incidence function (CIF) to estimate the probability of arthritis development,²⁶⁻²⁹ Gray's homogeneity test to compare the CIF estimates between groups, and Fine and Gray regression models.³⁰ The significance level was set at 0.05. All statistical analyses were performed using R software, V.3.4.2 (R Foundation for Statistical Computing, Vienna, Austria).
## Results

Across both cohorts, a total of 384 patients were included and the mean follow-up was 33.0 (±20.9) months. 56 out of the 384 patients with PsO (14.6%) developed new-onset PsA. The flow chart of the incident cases of PsA among the cohorts is reported in [figure 1](#).

### Frequency of new-onset clinical PsA among subclinical PsA

311 of 384 (80.9%) fitted within the subclinical PsA category, and the incidence rate of new-onset PsA was 7.7 per 100 patient-years in this group. The overall probability of new-onset PsA in subclinical PsA, estimated by the CIF, was 2.6% (95% CI 1.2% to 4.8%) at month 3, 4.9% (95% CI 2.9% to 7.7%) at month 6, 9.4% (95% CI 6.4% to 13.0%) at month 12, 18% (95% CI 13.6% to 23.0%) at month 24 and 22.7% (95% CI 17.2% to 28.6%) at month 36 ([figure 2](#)). The probability of new-onset PsA for each cohort of subclinical PsA is provided in [online supplemental figure 1](#). Among the RAPSODI cohort, subclinical PsA displayed an 11.7-fold increased risk of PsA development compared with PsO (HR=11.7 (95% CI 1.57 to 86.7), p=0.016) and the comparison of CIF estimation between subclinical PsA and PsO is provided in [figure 3](#).

### Clinical features and phenotypes of new-onset clinical PsA

Regarding the prevalent patterns of presentation of new-onset PsA, peripheral arthritis was the predominant pattern in 46 of 56 (82.1%) patients followed by enthesitis in 7 of 56 (12.5%), axial in 2 of 56 (3.6%) and dactylitic pattern in 1 of 56 (1.8%) ([figure 4](#)). Within patients with peripheral arthritis as the predominant pattern, 43 of 56 (76.8%) had oligoarthritis and 3 of 56 (5.3%) polyarthritis. Among the 56 new-onset PsA, the median swollen joint count was 1 (IQR 1–2), the median tender joint count was 2 (IQR 0–4) and the median LEI score was 1 (IQR 0–2) ([table 1](#)). The clinical presentation of new-onset PsA is represented in [figure 5](#).
<figure><img src="image_2.png" /><figcaption>Figure 1</figcaption></figure>

Flow chart of the selection of patients among the cohorts. PACE, Psoriasis and Psoriatic Arthritis Cohort Erlangen; PsA, psoriatic arthritis; PsO, psoriasis; RAPSODI, Ultrasonographic risk factors to develop psoriatic arthritis in psoriatic patients with and without clinical arthralgia study.
<figure><img src="image_3.png" /><figcaption>**Figure 2**
The arthritis development probability in subclinical PsA. CIF, cumulative incidence function; PsA, psoriatic arthritis.</figcaption></figure>
<figure><img src="image_4.png" /><figcaption>**Figure 3**
The comparison of arthritis development probability in subclinical PsA versus PsO without arthralgia in the RAPSODI cohort. CIF, cumulative incidence function; PsA, psoriatic arthritis; PsO, psoriasis; RAPSODI, Ultrasonographic risk factors to develop pSoriatic arthritis in psoriatic patients with and without clinical arthralgia study.</figcaption></figure>
<figure><img src="image_5.png" /><figcaption>Figure 4
Clinical phenotype of new-onset psoriatic arthritis (PsA).</figcaption></figure>
<figure><img src="image_6.png" /></figure>

* Download figure

* Open in new tab

* Download powerpoint

<caption>**Figure 5** Graphic description of clinical manifestation at psoriatic arthritis onset. Joint involvement (according to tender and/or swollen joints) and enthesal involvement (according to Leeds Enthesitis Index).</caption>
Baseline features of new-onset PsA (Table 1)

At PsA onset, patients had a median duration of morning stiffness of 15 (IQR 0–45) min and the mean pain Visual Analogue Scale was 49.2 (±24.4) mm.

Clinical characterisation of MSK symptoms before PsA onset

The pattern of MSK involvement prior to a diagnosis of PsA, during the follow-up was as follows (figure 6):

1. 16.1% (9 of 56) of patients with future-onset PsA had an inflammatory pattern before the PsA development with a mean duration before PsA diagnosis of 1.9 (±2.0) months (median 1 (IQR 1–1) months).

2. 41.1% (23 of 56) had non-inflammatory pattern and for these patients, we noted a long duration of symptoms before PsA diagnosis, with a mean of 57.2 (±92.6) months (median 27 (IQR 4.5–37) months).

3. 42.8% (24 of 56) had mixed pattern characterised by first non-inflammatory symptoms with a mean duration before PsA diagnosis of 22.8 (±64.5) months (median 9.5 (IQR 4–14.75) months) followed by inflammatory symptoms (mean 3.9±3.6 months; median 3 (IQR 1.75–5.25) months).

Subclinical PsA

<figure><img src="image_7.png" /></figure>

• [Download figure](#)

• [Open in new tab](#)

• [Download powerpoint](#)

<caption>**Figure 6**
Patterns of musculoskeletal (MSK) symptoms before psoriatic arthritis (PsA) onset.</caption>
Discussion

Prior studies in subjects with PsO, not enriched for arthralgia, showed that the development of
arthralgia was associated with later PsA development.⁹ ¹⁰ ¹⁵ Therefore, we evaluated two PsO
cohorts enriched for arthralgia to shed light on the transition from PsO to PsA. In patients with PsO
regarded as subclinical PsA, we estimated a probability of PsA development of 9.4% after 12
months of follow-up and 22.7% after 36 months. The annual incidence rate of PsA development
from population-based and psoriasis registry has been reported between 0.3% and 3.7% and so
our findings suggest a substantial enrichment.⁷ We found peripheral arthritis as the major pattern
of presentation (82.1%) and in particular, oligoarthritis was very frequent. Finally, MSK symptoms
were usually of long duration and ‘non-inflammatory’ in nature in many cases in the months
preceding PsA diagnosis.

The low incidence rate of PsA development in patients with PsO is the major determinant for
limited data on the clinical characterisation of new-onset PsA, since prospective cohorts including a
large number of patients with PsO followed for many years are needed to achieve an adequate
number of cases of PsA development to allow early disease characterisation.⁶ To overcome these
limitations, studies focusing on the transition to PsA, enrolling patients with PsO at higher risk of
short-term/imminent PsA development, have been analysed here.

We noted that peripheral arthritis was the main phenotype of new-onset of PsA with the majority of
patients showing at least one swollen joint/digit, with a median swollen joint count of 1 and tender
joint count of 2 indicating an oligoarthritis pattern as the typical presentation of new-onset PsA.
These findings are in coherence with other reports focusing on the transition from PsO to PsA,
reporting a mean number of active joints between 1 and 3.<sup>6 31 32</sup> Studies examining inception
cohorts of early PsA cases have also documented oligoarthritis and polyarthritis as frequently
observed clinical presentations.<sup>33-35</sup> Furthermore, the frequency of dactylitis at the PsA diagnosis
(3.6%) reported in this study is notably lower compared with what is noted in early PsA inception
cohorts with approximately 40-50% of patients presenting dactylitis at the time of diagnosis.<sup>35</sup>
<sup>36</sup> However, our data about the frequency of dactylitis align with the low disease activity observed
in our patients with new-onset PsA, as the presence of dactylitis appears to be associated with a
polyarticular pattern and higher disease activity. The development of polyarthritis and dactylitis
likely reflects disease spread or evolution.

Our results confirm the need of characterisation of arthralgia in terms of pain (eg, non-inflammatory vs inflammatory pain), sites involved and duration of symptoms in order to optimise the therapeutic targeting of subclinical PsA. Differently from RA, a substantial number of patients reported non-inflammatory MSK pain before the PsA onset, highlighting the importance and difficulty in understanding symptomatology in the subclinical PsA arena but it is noteworthy that the non-inflammatory groups had a much longer duration to PsA onset, that is very relevant for duration of prevention trial design.<sup>37</sup> Conversely, the ‘pure’ inflammatory pattern seemed to be a subacute onset with a short duration of inflammatory symptoms prior to PsA diagnosis.

This study has some limitations. First, we included two cohorts that had different inclusion criteria
but still showed a similar expression of subclinical PsA due to the presence of arthralgia. Moreover,
the heterogeneity of imaging data (in terms of imaging used and sites evaluated) did not allow us
to analyse these data collectively. Furthermore, the objective assessment of synovitis (ie, swelling)
is easier than enthesitis or axial disease which may have facilitated the higher rate of synovitis as
the main recognised feature of new-onset disease. Moreover, our sample size is not very large;
however, it is the first study focusing on subclinical PsA and our results are in coherence with other
studies in terms of patient characteristics at the PsA onset, indicating the validity of our results.<sup>6 31</sup>
<sup>32</sup> Finally, the description of symptoms before PsA onset was retrospectively collected leading to a
low level of granularity.

In conclusion, the present study provides new insights into the subclinical phases of PsA. We have
confirmed that patients with PsO experiencing unexplained arthralgia, also reporting non-
inflammatory symptoms, are at a significantly elevated risk of developing PsA. Additionally,
peripheral arthritis, mainly oligoarthritis, is the most common PsA presentation in cohorts with PsO enriched for arthralgia.

This study underscores the need to improve the characterisation of symptoms during the subclinical phase, as it can greatly enhance our ability to identify PsA at an early stage and facilitate prompt diagnosis and prevention/interception of PsA.

## Ethics approval

This study involves human participants. Ethical approvals for the studies were obtained at both centres (RAPSODI, approval number 706 ASU FC; PACE, approval number 86_21 Bc). Participants gave informed consent to participate in the study before taking part.

## References

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-17.

2. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019 Mar;15(3):153-66.

3. Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nat Rev Rheumatol. 2021 Apr;17(4):238-43.

4. De Marco G, Zabotti A, Baraliakos X, Iagnocco A, Aletaha D, Gisondi P, et al. Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce. RMD Open. 2023 Jun;9(2):e003143.

5. Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. Rheumatol Ther [Internet]. 2021 Oct 1 [cited 2021 Oct 1]; Available from: https://doi.org/10.1007/s40744-021-00378-w

6. McGonagle DG, Zabotti A, Watad A, Bridgewood C, De Marco G, Kerschbaumer A, et al. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free? Ann Rheum Dis. 2022 Jan;81(1):7-10.

7. Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023 Jun 9;ard-2023-224148.

8. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12.

9. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-79.

10. Richette P, Vis M, Ohrndorf S, Tillett W, Ramírez J, Neuhold M, et al. Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA. RMD Open. 2023 Mar;9(1):e002934.

11. Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019 Oct;5(2):e001067.

12. Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Sokolova MV, et al. Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis Rheumatol Hoboken NJ. 2022 Feb;74(2):253-62.

13. Faustini F, Simon D, Oliveira I, Kleyer A, Haschka J, Englbrecht M, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016 Dec;75(12):2068-74.

14. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis
Rheum. 2006 Aug;54(8):2665-73.

15. Härle P, Hartung W, Lehmann P, Ehrenstein B, Schneider N, Müller H, et al. [Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting]. Z Rheumatol. 2010 Mar;69(2):157-60, 162-3.

16. Balint PV, Terslev L, Aegerter P, Bruyn GAW, Chary-Valckenaere I, Gandjbakhch F, et al. Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative. Ann Rheum Dis. 2018;77(12):1730-5.

17. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009 Jun;68(6):770-6.

18. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83.

19. Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol Hoboken NJ. 2016 Apr;68(4):915-23.

20. Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022 Jan;81(1):68-73.

21. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatol Oxf Engl. 2003 Dec;42(12):1460-8.

22. Kasiem FR, Luime JJ, Vis M, Kok MR, Wervers K, Gerards AH, et al. Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic ARthritis study. Scand J Rheumatol. 2021 Mar;50(2):124-31.

23. Dubash S, Alabas OA, Michelena X, Garcia-Montoya L, Wakefield RJ, Helliwell PS, et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Ann Rheum Dis. 2022 Apr;81(4):490-5.

24. McGonagle D, Lories RJU, Tan AL, Benjamin M. The concept of a 'synovio-enthesseal complex' and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007 Aug;56(8):2482-91.

25. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet Lond Engl. 1998 Oct 3;352(9134):1137-40.

* **Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

* **Competing interests** AZ—speakers bureau: AbbVie, Novartis, Janssen, Lilly, UCB, Amgen; paid instructor for: AbbVie, Novartis, UCB. FF—none declared. LG—consultant of: AbbVie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, UCB; grant/research support from: Sandoz, UCB. IG—none declared. MS—none declared. AT—none declared. XB—speakers bureau: AbbVie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly; paid instructor for: AbbVie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly; consultant of: AbbVie, BMS, MSD, Sandoz, Novartis, Pfizer, Galapagos, UCB, Lilly; grant/research support from: AbbVie, MSD, Novartis; leadership or fiduciary role in other board, society, committee or advocacy groups, paid or unpaid; editorial board member of *Annals of Rheumatic Diseases*; ASAS president. GDM—none declared. SDV—none declared. EE—consultant of: AbbVie, Janssen, Novartis, Amgen. LQ—none declared. ES—none declared. JSS—consulting fees: AbbVie, Galapagos/Gilead, Novartis-Sandoz, BMS, Samsung Sanofi, Chugai R-Pharma, Lilly; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Samsung, Lilly, R-Pharma, Chugai, MSD, Janssen Novartis-Sandoz; editor-in-chief of *Annals of Rheumatic Diseases*. IT—none declared. AW—none declared. GS—none declared. DGM—speakers bureau: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB; consultant of: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB; grant/research support from: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer. DS—none declared.
<table><caption>**Table 1.** Baseline features of new onset PsA. Legend: ACPA: anti-citrullinated peptide antibody; BMI: Body Mass Index; CRP: C-reactive protein; DMARD: disease modifying antirheumatic drug; LEI: Leeds Enthesitis Index; MRI: magnetic resonance imaging; PASI: Psoriasis Area Severity Index; RF: Rheumatoid Factor; SD: standard deviation.</caption><thead><tr><th colspan="2">Baseline features of new onset PsA (N = 56)</th></tr></thead><tbody><tr><th colspan="2">Demographic features</th></tr><tr><td>Age, years, mean (±SD)</td><td>50.2<br>(±13.1)</td></tr><tr><td>Gender, Male, n/N (%)</td><td>34/56<br>(60,1%)</td></tr><tr><td>BMI, mean (±SD)</td><td>32.0 (±8.1)</td></tr><tr><td>Systemic treatment before PsA diagnosis (yes=1), n/N (%)</td><td>8/56<br>(14.3%)</td></tr><tr><td>Conventional DMARDs before PsA diagnosis (yes=1), n/N (%)</td><td>6/56<br>(10.7%)</td></tr><tr><td>Biological DMARDs before PsA diagnosis (yes=1), n/N (%)</td><td>5/56 (8.9%)</td></tr><tr><th colspan="2">Clinical examination</th></tr><tr><td>Swollen Joint Count (66), median (IQR)</td><td>1 (1)</td></tr><tr><td>Swollen Joint Count (66), mean (±SD)</td><td>1.4 (±1.1)</td></tr><tr><td>Tender Joint Count (68), median (IQR)</td><td>2 (4.25)</td></tr><tr><td>Tender Joint Count (68), mean (±SD)</td><td>3.0 (±3.8)</td></tr><tr><td>Dactylitis at the onset, n/N (%)</td><td>2/56 (3.6%)</td></tr><tr><td>LEI, median (IQR) – mean (±SD)</td><td>0 (1)</td></tr><tr><td>LEI, mean (±SD)</td><td>0.4 (±0.9)</td></tr><tr><th colspan="2">Laboratory and imaging features</th></tr><tr><td>CRP (mg/dL), mean (±SD)</td><td>0.77<br>(±1.36)</td></tr><tr><td>RF, n (%)</td><td>1 (1.8%)</td></tr><tr><td>ACPA, n</td><td>0</td></tr><tr><td>Sacroiliitis at X-ray or MRI, n (%)</td><td>6 (10.7%)</td></tr></tbody></table>
<figure><img src="image_8.png" /><figcaption>**Supplementary Figure 1.** The Arthritis Development probability in subclinical PsA in the PACE and RAPSODI cohort. CIF: cumulative incidence function</figcaption></figure>